# A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)

> **NCT04516096** · PHASE2,PHASE3 · COMPLETED · sponsor: **Amylyx Pharmaceuticals Inc.** · enrollment: 28 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** AMX0035

## Key facts

- **NCT ID:** NCT04516096
- **Lead sponsor:** Amylyx Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-22
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-01-31
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04516096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04516096, "A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04516096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*